Mydriasis Market

Market Overview:

The 7 major mydriasis markets reached a value of USD 641.5 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,230.5 Million by 2035, exhibiting a growth rate (CAGR) of 6.10% during 2025-2035.

The mydriasis market has been comprehensively analyzed in IMARC's new report titled "Mydriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035".  Mydriasis refers to a medical disorder in which the pupil of the eye remains abnormally dilated and fails to constrict properly in response to changes in lighting conditions or other stimuli. This can result in increased sensitivity to light, glare, and difficulties with vision, especially in a bright environment. Additionally, individuals suffering from mydriasis may experience blurred vision or problems with focusing, particularly when transitioning between different lighting conditions. The presence of other accompanying indications will depend on the underlying cause of mydriasis, which may include symptoms related to medication side effects, eye diseases, neurological disorders, or systemic conditions. The diagnostic process generally begins with a thorough medical history and physical examination, including an assessment of the eyes, neurological functioning, as well as the evaluation of any associated symptoms. Numerous specialized diagnostic procedures may be conducted, such as pupillometry to objectively measure pupillary responses, imaging studies like MRI or CT scans to assess structural abnormalities, and laboratory tests to investigate systemic conditions or drug-related causes.

The rising cases of several eye disorders, such as uveitis, iritis, glaucoma, ocular trauma, etc., that affect the normal functioning of the iris muscles are primarily driving the mydriasis market. Furthermore, the widespread adoption of alpha-adrenergic agonist eye drops, including apraclonidine or brimonidine, to constrict the dilated pupil and reduce light sensitivity is acting as another significant growth-inducing factor. Additionally, the inflating utilization of pupil constriction exercises, which involve performing specific eye exercises that help in stimulating the muscles responsible for controlling the size of the pupil, is also augmenting the market growth. Moreover, the escalating demand for surgical procedures to correct anatomical issues, repair damaged structures, as well as alleviate underlying neurological problems that contribute to mydriasis is creating a positive outlook for the market. Apart from this, the ongoing advancements in imaging technologies, such as the introduction of high-resolution digital imaging and anterior segment optical coherence tomography, which have improved the visualization of the anterior segment of the eye, including the iris and pupil, are expected to drive the mydriasis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the mydriasis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for mydriasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mydriasis market in any manner.

Recent Developments:

• In September 2023, Viatris and Ocuphire disclosed the U.S. commercial launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the management of pharmacologically-induced mydriasis caused by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide). Ryzumvi is the first U.S. commercially available FDA-approved eye solution that reverses dilatation.

Key Highlights:

• According to estimates, the United States has the highest prevalence of mydriasis.
• An estimated one in every five persons is born with slightly different-sized pupils, and their eyes typically react to changes in light.
• Pupil size following mydriasis is primarily hereditary, with a heritability of up to 80%.

Drugs:

RYZUMVI is the first and only relatively non-selective alpha-1 and alpha-2 adrenergic antagonist approved to reverse pharmacologically-induced mydriasis.  Ryzumvi reversibly binds to alpha-1 adrenergic receptors on the radial iris dilator muscle, thereby reducing pupil diameter, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the mydriasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the mydriasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current mydriasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the mydriasis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the mydriasis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the mydriasis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of mydriasis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of mydriasis by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of mydriasis by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with mydriasis across the seven major markets?
• What is the size of the mydriasis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of mydriasis?
• What will be the growth rate of patients across the seven major markets?

Mydriasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for mydriasis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mydriasis market?
• What are the key regulatory events related to the mydriasis market?
• What is the structure of clinical trial landscape by status related to the mydriasis market?
• What is the structure of clinical trial landscape by phase related to the mydriasis market?
• What is the structure of clinical trial landscape by route of administration related to the mydriasis market?